Drugs / OG-6219
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05560646 | Oct 2022 → May 2025 | endometriosis | Organon and Co | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-07-02 | Organon and Co | Results Organon Provides Update on Phase 2 ELENA Proof-of-Concept Study Evaluating OG-6219 in Patients with Endometriosis-Related Pain organon.com ↗
Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, today announced that the Phase 2 ELENA proof-of-concept study evaluating the investigational candidate OG-6219 in endometriosis-related pain did not meet its primary efficacy endpoint. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-07-02 | Organon and Co | Organon Provides Update on Phase 2 ELENA Proof-of-Concept Study Evaluating OG-6219 in Patients with Endometriosis-Related Pain organon.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OG-6219 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05560646 ↗ |
| Route | Oral | “Participants will receive (orally) OG-6219 tablets during treatment cycles.” NCT05560646 ↗ |